G-CSF Polymer Conjugate Formulation pH Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compositions for G-CSF are not stable at elevated temperatures and often require reconstitution, causing patient irritation due to acidic pH levels.
Innovation Solution
Aqueous pharmaceutical formulations with a pH range of 4.5 to 5.5, containing a polymer-G-CSF conjugate and a surfactant, are developed to enhance stability and reduce irritation by preventing acid hydrolysis and eliminating the need for reconstitution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If existing pharmaceutical compositions for G-CSF are used, then the drug can be administered, but the formulations are not stable at elevated temperatures and require reconstitution
Solution Approach 1:
The polymer conjugation is performed in advance during manufacturing to create a pre-stabilized G-CSF formulation that does not require reconstitution before administration. This preliminary modification ensures the product is ready-to-use while improving thermal stability.
Solution Approach 2:
A composite formulation is created by conjugating a polymer (such as PEG) to the G-CSF protein, resulting in a hybrid molecule that combines the biological activity of G-CSF with the stability and pharmacokinetic properties of the polymer, eliminating the need for reconstitution.
2Ease of manufacture
If acidic pH formulations are used for G-CSF, then the drug can be formulated, but patient irritation increases
Solution Approach 1:
The pH of the formulation is adjusted from highly acidic levels to a more neutral or mildly acidic range (closer to physiological pH), reducing the irritant effect on patient tissues while maintaining the stability and efficacy of the G-CSF polymer conjugate.
3Stability of the object's composition
If polymer conjugation is applied to G-CSF, then storage stability improves, but manufacturing complexity increases
Solution Approach 1:
A polymer conjugation technique is employed as an intermediary method to attach a stabilizing polymer to the G-CSF protein, improving storage stability while using established biochemical methods to manage manufacturing complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations maintain stability at temperatures above refrigerator levels without significant activity loss and reduce patient irritation by maintaining a less acidic pH, ensuring prolonged storage and ready-to-use convenience.
Implementation Method 1
The conjugate shows resistance to acid hydrolysis and maintains its biological activity at temperatures above refrigerator levels
Implementation Method 2
The composition comprises a polymer-G-CSF conjugate and a surfactant
Data Source
AI summary
The present invention relates to a liquid pharmaceutical composition comprising a granulocyte colony stimulating factor polypeptide conjugated with a polymer. In various embodiments, the composition has a pH value in the range of 4.5 to 5.5. Exemplary compositions further comprise a surfactant and optionally one or more other pharmaceutically acceptable excipients. The invention provides, inter alia, formulations free from tartaric acid or salts thereof and/or from succinic acid and salts thereof as buffering agents. Exemplary formulations are essentially devoid of not amino acids as stabilizers. The composition has good storage stability and is especially useful for the prophylaxis and treatment of disorders and medical indications where granulocyte colony stimulating factor preparations are considered as useful remedies.